{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:22:36Z","timestamp":1792732956498,"version":"4.5.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.kint.2024.12.021","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T11:15:30Z","timestamp":1740050130000},"page":"816-824","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["The prevention and management of chronic kidney disease among patients with metabolic syndrome"],"prefix":"10.1016","volume":"107","author":[{"given":"Doreen","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parminder K.","family":"Judge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9507-5301","authenticated-orcid":false,"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Haynes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1172-8243","authenticated-orcid":false,"given":"William G.","family":"Herrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2024.12.021_bib1","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S","article-title":"Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation","volume":"15","author":"Alberti","year":"1998","journal-title":"Diabet Med"},{"key":"10.1016\/j.kint.2024.12.021_bib2","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0140-6736(05)67402-8","article-title":"The metabolic syndrome--a new worldwide definition","volume":"366","author":"Alberti","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2024.12.021_bib3","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/01.crd.0000380842.14048.7e","article-title":"Diagnosis and management of the metabolic syndrome. An American Heart Association\/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary","volume":"13","author":"American Heart Association; National Heart, Lung, and Blood Institute","year":"2005","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.kint.2024.12.021_bib4","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2024.12.021_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2022.109924","article-title":"Geographic distribution of metabolic syndrome and its components in the general adult population: a meta-analysis of global data from 28 million individuals","volume":"188","author":"Noubiap","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.kint.2024.12.021_bib6","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11906-018-0812-z","article-title":"The global epidemic of the metabolic syndrome","volume":"20","author":"Saklayen","year":"2018","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.kint.2024.12.021_bib7","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.dsx.2018.12.006","article-title":"Metabolic syndrome and its components are related to a higher risk for albuminuria and proteinuria: evidence from a meta-analysis on 10,603,067 subjects from 57 studies","volume":"13","author":"Rashidbeygi","year":"2019","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.kint.2024.12.021_bib8","first-page":"1614","article-title":"The effect of metabolic syndrome and its individual components on renal function: a meta-analysis","volume":"12","author":"Li","year":"2023","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.kint.2024.12.021_bib9","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2024.12.021_bib10","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A\u00a0synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2024.12.021_bib11","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S2213-8587(18)30313-9","article-title":"Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies","volume":"7","author":"Coresh","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.kint.2024.12.021_bib12","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jama.286.4.421","article-title":"Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals","volume":"286","author":"Gerstein","year":"2001","journal-title":"JAMA"},{"issue":"4S","key":"10.1016\/j.kint.2024.12.021_bib13","first-page":"S117","article-title":"KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.12.021_bib14","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1161\/HYPERTENSIONAHA.121.17323","article-title":"Albuminuria testing in hypertension and diabetes: an individual-participant data meta-analysis in a global consortium","volume":"78","author":"Shin","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2024.12.021_bib15","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1001\/jama.2011.451","article-title":"A\u00a0predictive model for progression of chronic kidney disease to kidney failure","volume":"305","author":"Tangri","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2024.12.021_bib16","series-title":"Evidence review for the best combination of measures to identify increased risk of progression in adults, children and young people: chronic kidney disease: evidence review F","year":"2021"},{"key":"10.1016\/j.kint.2024.12.021_bib17","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1093\/ndt\/gfz018","article-title":"Towards the best kidney failure prediction tool: a systematic review and selection aid","volume":"35","author":"Ramspek","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2024.12.021_bib18","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.2337\/dc22-0698","article-title":"Development and validation of prediction models of adverse kidney outcomes in the population with and without diabetes","volume":"45","author":"Grams","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kint.2024.12.021_bib19","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","article-title":"Development and validation of the American Heart Association's PREVENT equations","volume":"149","author":"Khan","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2024.12.021_bib20","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.kint.2019.02.022","article-title":"Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"95","author":"House","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.12.021_bib21","doi-asserted-by":"crossref","first-page":"k5301","DOI":"10.1136\/bmj.k5301","article-title":"Adiposity and risk of decline in glomerular filtration rate: meta-analysis of individual participant data in a global consortium","volume":"364","author":"Chang","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.kint.2024.12.021_bib22","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/j.ajkd.2008.02.363","article-title":"Waist-to-hip ratio, body mass index, and subsequent kidney disease and death","volume":"52","author":"Elsayed","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2024.12.021_bib23","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1681\/ASN.2020050679","article-title":"Conventional and genetic evidence on the association between adiposity and CKD","volume":"32","author":"Zhu","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.12.021_bib24","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1161\/CIRCRESAHA.118.312669","article-title":"Sedentary behavior, exercise, and cardiovascular health","volume":"124","author":"Lavie","year":"2019","journal-title":"Circ Res"},{"key":"10.1016\/j.kint.2024.12.021_bib25","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1053\/j.ajkd.2014.03.020","article-title":"Exercise training in adults with CKD: a systematic review and meta-analysis","volume":"64","author":"Heiwe","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2024.12.021_bib26","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S2213-8587(14)70156-1","article-title":"Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial","volume":"2","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.kint.2024.12.021_bib27","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa1212914","article-title":"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes","volume":"369","author":"Look AHEAD Research Group","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2024.12.021_bib28","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1161\/CIRCRESAHA.115.307611","article-title":"Epidemiology of atherosclerosis and the potential to reduce the global burden of atherothrombotic disease","volume":"118","author":"Herrington","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.kint.2024.12.021_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241310449","article-title":"Emerging role of GLP-1 agonists in obesity: a comprehensive review of randomised controlled trials","volume":"24","author":"Popoviciu","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.kint.2024.12.021_bib30","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2024.12.021_bib31","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1038\/s41591-024-03015-5","article-title":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","volume":"30","author":"Colhoun","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.kint.2024.12.021_bib32","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2024.12.021_bib33","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.kint.2020.05.048","article-title":"Blood pressure and kidney disease: chicken or egg (or both)?","volume":"98","author":"Staplin","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.12.021_bib34","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.kint.2020.04.044","article-title":"A\u00a0bidirectional Mendelian randomization study supports causal effects of kidney function on blood pressure","volume":"98","author":"Yu","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.12.021_bib35","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1161\/HYPERTENSIONAHA.122.19354","article-title":"Determining the relationship between blood pressure, kidney function, and chronic kidney disease: insights from genetic epidemiology","volume":"79","author":"Staplin","year":"2022","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2024.12.021_bib36","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0140-6736(15)00805-3","article-title":"Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis","volume":"387","author":"Xie","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2024.12.021_bib37","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2024.12.021_bib38","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","article-title":"Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies","volume":"360","author":"Lewington","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2024.12.021_bib39","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A\u00a0randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"SPRINT Research Group","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2024.12.021_bib40","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1681\/ASN.2017020148","article-title":"Effects of intensive BP control in CKD","volume":"28","author":"Cheung","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.12.021_bib41","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S2213-8587(22)00172-3","article-title":"Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis","volume":"10","author":"Nazarzadeh","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.kint.2024.12.021_bib42","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jama.2014.18574","article-title":"Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis","volume":"313","author":"Emdin","year":"2015","journal-title":"JAMA"},{"issue":"3S","key":"10.1016\/j.kint.2024.12.021_bib43","first-page":"S1","article-title":"KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"99","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.12.021_bib44","doi-asserted-by":"crossref","first-page":"H1219","DOI":"10.1152\/ajpheart.00796.2011","article-title":"The renin-angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome","volume":"302","author":"Putnam","year":"2012","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.kint.2024.12.021_bib45","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2024.12.021_bib46","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2024.12.021_bib47","doi-asserted-by":"crossref","first-page":"298","DOI":"10.7326\/0003-4819-137-4-200208200-00026","article-title":"Effect of angiotensin-converting enzyme inhibitors on progression of nondiabetic renal disease","volume":"137","author":"Jafar","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.kint.2024.12.021_bib48","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/ajh\/hpaa137","article-title":"Aldosterone, inflammation, immune system, and hypertension","volume":"34","author":"Ferreira","year":"2021","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.kint.2024.12.021_bib49","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/s41440-022-00913-4","article-title":"Aldosterone breakthrough from a pharmacological perspective","volume":"45","author":"Mogi","year":"2022","journal-title":"Hypertens Res"},{"key":"10.1016\/j.kint.2024.12.021_bib50","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1038\/s41591-024-03264-4","article-title":"Finerenone in heart failure and chronic kidney disease with type 2 diabetes: the FINE-HEART pooled analysis of cardiovascular, kidney, and mortality outcomes","volume":"30","author":"Vaduganathan","year":"2024","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.kint.2024.12.021_bib51","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.kisu.2021.11.008","article-title":"Considerations for the future: current and future treatment paradigms with mineralocorticoid receptor antagonists-unmet needs and underserved patient cohorts","author":"Epstein","year":"2022","journal-title":"Kidney Int Suppl (2011)"},{"key":"10.1016\/j.kint.2024.12.021_bib53","article-title":"The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial","author":"Judge","year":"2024","journal-title":"Nephrol Dial Transplant"},{"issue":"99","key":"10.1016\/j.kint.2024.12.021_bib54","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1111\/j.1523-1755.2005.09916.x","article-title":"Dyslipidemia and the progression of renal disease in chronic renal failure patients","author":"Cases","year":"2005","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.kint.2024.12.021_bib55","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1681\/ASN.2013090965","article-title":"Effects of lowering LDL cholesterol on progression of kidney disease","volume":"25","author":"Haynes","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.12.021_bib56","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2024.12.021_bib57","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2213-8587(16)30156-5","article-title":"Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials","volume":"4","author":"Cholesterol Treatment Trialists' Collaboration","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.kint.2024.12.021_bib58","doi-asserted-by":"crossref","first-page":"182","DOI":"10.7326\/M13-2453","article-title":"Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline","volume":"160","author":"Tonelli","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.kint.2024.12.021_bib59","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.kint.2017.12.011","article-title":"Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease","volume":"93","author":"Toth","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.12.021_bib60","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.kint.2018.01.030","article-title":"PCSK9 inhibition: ready for prime time in CKD?","volume":"93","author":"Mafham","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.12.021_bib61","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2024.12.021_bib62","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/cts.13202","article-title":"Pharmacokinetics of bempedoic acid in patients with renal impairment","volume":"15","author":"Amore","year":"2022","journal-title":"Clin Transl Sci"},{"issue":"5S","key":"10.1016\/j.kint.2024.12.021_bib63","first-page":"S1","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.12.021_bib64","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S2213-8587(17)30104-3","article-title":"Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials","volume":"5","author":"Zoungas","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.kint.2024.12.021_bib65","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.kint.2024.12.021_bib66","doi-asserted-by":"crossref","first-page":"694","DOI":"10.2337\/dc15-2322","article-title":"Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON","volume":"39","author":"Wong","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kint.2024.12.021_bib67","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1007\/s00125-009-1470-0","article-title":"Intensive glucose control and macrovascular outcomes in type 2 diabetes","volume":"52","author":"Control Group","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.kint.2024.12.021_bib68","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2024.12.021_bib69","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.kint.2024.12.021_bib70","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2024.12.021_bib71","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/289645","article-title":"Chronic inflammation in obesity and the metabolic syndrome","volume":"2010","author":"Monteiro","year":"2010","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.kint.2024.12.021_bib72","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2024.12.021_bib73","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2024.12.021_bib74","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2024.12.021_bib75","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Ridker","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2024.12.021_bib76","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.kint.2024.12.021_bib77","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2213-8587(24)00155-4","article-title":"Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials","volume":"12","author":"Apperloo","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.kint.2024.12.021_bib78","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","article-title":"Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials","volume":"145","author":"Neuen","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2024.12.021_bib79","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","article-title":"Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial","volume":"403","author":"Tuttle","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2024.12.021_bib80","article-title":"Discontinuation and reinitiation of SGLT-2 inhibitors and GLP-1R agonists in patients with type 2 diabetes: a nationwide study from 2013 to 2021","volume":"29","author":"Malik","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.kint.2024.12.021_bib81","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJMoa2409183","article-title":"Long-term effects of empagliflozin in patients with chronic kidney disease","volume":"392","author":"The EMPA-KIDNEY Collaborative Group","year":"2025","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2024.12.021_bib82","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.120.007264","article-title":"Cardio-renal-metabolic care models: toward achieving effective interdisciplinary care","volume":"13","author":"Rangaswami","year":"2020","journal-title":"Circ Cardiovasc Qual Outcomes"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253825001413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253825001413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:26:18Z","timestamp":1777695978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253825001413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":81,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0085253825001413"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2024.12.021","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The prevention and management of chronic kidney disease among patients with metabolic syndrome","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2024.12.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}